Early Cancer Institute Seminar: Dr Mireia Crispin

The seminar series from the Early Cancer Institute aims to connect researchers in the early cancer detection and diagnosis space to share knowledge and spark collaboration. Join fellow researchers for lunch and an opportunity to network.

On Tuesday 23rd January we welcome Dr Mireia Crispin, Assistant Professor in Integrated Cancer Medicine at the University of Cambridge and co-lead of the CRUK Cambridge Centre Ovarian Cancer Programme, to give a talk: 'Screening for kidney cancer: can AI help?'

This event will take place in the Early Cancer Institute, Adrian Way, Cambridge Biomedical Campus, Cambridge, CB2 0XZ

Lunch is provided from 12:30pm, the talk will begin at 1.00pm followed by a Q&A. Please ensure you arrive promptly.

Speaker Biography:

Dr Mireia Crispin, Assistant Professor and Group Leader
Department of Oncology, University of Cambridge

Co-Lead, Ovarian Cancer Programme, Co-Lead, Mark Foundation Institute for Integrated Cancer Medicine, Cancer Research UK Cambridge Centre

Chief Digital Officer, 52North Health

Dr Mireia Crispin is an Assistant Professor in the Department of Oncology of the University of Cambridge, and leads a research group focusing on the development of multi-omic data integration models to understand response cancer therapies. She co-leads the Ovarian Programme at the CRUK Cancer Centre, and the Mark Foundation Institute for Integrated Cancer Medicine. She is also the Chief Digital Officer of 52 North Health, an award-winning biotech start-up developing affordable at-home tests for cancer patients. Dr Crispin worked previously at Memorial Sloan Kettering Cancer Center in New York, and was the Director of the Healthcare Innovation programme of the Center for the Governance of Change at IE University (Madrid, Spain), focusing on policy challenges for the integration of AI and digital health in European healthcare. She holds a PhD in Particle Physics (University of Oxford, 2015). She is an author in over 400 publications and has received numerous national and international awards, most recently finalist of the Cancer Research Horizons Early-Career Entrepreneur of the Year 2022 award.